The molecular structure and pathological functions of Syndecan-1/CD138, and the application of its fluorescently labeled protein in tumor research

Author: Senior Product Manager of UA Views：101

This article systematically elaborates on the molecular structural characteristics of Syndecan-1 (CD138) as a core member of the heparan sulfate proteoglycan family, its regulatory mechanisms of expression under physiological and pathological conditions, and its research progress in tumorigenesis, development, and liquid biopsy. On this basis, it also introduces the application value of fluorescence-labeled recombinant protein detection.

Recent Advances
Product Information

Recent Advances

Molecular Structure, Pathological Functions of Syndecan-1/CD138 and Applications of Fluorescently Labeled Proteins in Cancer Research

Summary: This article systematically elaborates on the molecular structural characteristics of Syndecan-1 (CD138) as a core member of the heparan sulfate proteoglycan family, its expression regulation patterns under physiological and pathological conditions, research progress in tumorigenesis and liquid biopsy, and introduces the detection application value of fluorescently labeled recombinant proteins.

I. Overview of the Syndecan Family and Molecular Structural Characteristics of Syndecan-1

Syndecans are a family of type I transmembrane heparan sulfate proteoglycans (HSPGs), consisting of four members in mammals: Syndecan-1 (SDC1, also known as CD138), Syndecan-2 (SDC2, or fibroglycan), Syndecan-3 (SDC3, or N-syndecan), and Syndecan-4 (SDC4, or amphiglycan). The family name derives from the Greek word "syndein," meaning "to bind together," accurately reflecting its biological essence as a cell surface molecule mediating multiple interactions between cells and the microenvironment.

Syndecan-1 is the most extensively studied and well-characterized member of this family. Its gene is located on human chromosome 2 (2p24.1), encoding a precursor protein of 310 amino acids. From a structural biology perspective, SDC1 is composed of three main domains arranged in sequence. The extracellular domain (ECD) at the N-terminus contains approximately 234 amino acid residues, featuring multiple glycosylation sites that covalently link heparan sulfate (HS) and chondroitin sulfate (CS) glycosaminoglycan chains, capable of carrying up to two HS chains and three CS chains. These negatively charged chains extend into the extracellular space, interacting with various growth factors, cytokines, chemokines, and extracellular matrix components. The transmembrane domain (TMD) consists of about 25 hydrophobic amino acids, including a highly conserved GXXXG dimerization motif that mediates homodimerization of SDC1 molecules and heterodimerization with other family members, while also participating in lipid raft localization. The cytoplasmic domain comprises approximately 34 amino acids, further divided into the membrane-proximal C1 region, the intermediate V variable region, and the distal C2 region. The C1 region connects to the actin cytoskeleton, while the C2 region contains the EFYA tetrapeptide sequence, binding to various PDZ domain-containing proteins (such as syntenin and syndetin) involved in signal transduction and vesicle transport. Due to extensive glycosaminoglycan chain modifications, the theoretical molecular weight of SDC1 is about 33 kDa, but the apparent molecular weight of the mature protein can range from 120 to 200 kDa.

II. Expression and Distribution Characteristics of Syndecan-1 in Normal Tissues

Under normal physiological conditions, Syndecan-1 expression exhibits high tissue specificity. SDC1 is primarily expressed in epithelial cells, including epidermal keratinocytes, mucosal epithelia of the digestive and respiratory tracts, as well as plasma cells and some mesenchymal-derived cells. In the hematopoietic system, SDC1 is mainly expressed on the surface of immature B cells and terminally differentiated plasma cells, making CD138 a specific marker for plasma cells. Additionally, SDC1 expression in various normal tissues is strictly regulated during development, showing spatiotemporal-specific expression patterns during embryogenesis, participating in physiological processes such as cell morphology maintenance, tissue repair, and inflammation regulation. Notably, SDC1 expression in normal epithelial cells exhibits polarized distribution characteristics, primarily localized on the cell membrane surface, forming an orderly interaction network with the extracellular matrix and adjacent cells.

III. Abnormal Expression and Functional Significance of Syndecan-1 in Tumors

Syndecan-1 exhibits significant abnormalities in expression levels and distribution patterns in various malignancies. In hematological tumors, SDC1 shows selective high expression on the surface of malignant plasma cells in multiple myeloma (MM), with its expression levels closely related to tumor proliferation, invasion, and drug resistance. Given the high expression of SDC1 in myeloma cells and its critical role in plasma cell biology, CD138 has become an important diagnostic marker and therapeutic target in this field. Antibody-drug conjugates targeting SDC1 (such as indatuximab-ravtansine) have shown therapeutic potential in clinical trials.

In solid tumors, SDC1 expression changes are more complex and tissue-specific. In many epithelial-derived cancers, SDC1 expression levels often decrease with tumor grade and progression, correlating with epithelial-mesenchymal transition (EMT)—loss of SDC1 is often accompanied by downregulation of E-cadherin and reduced cell adhesion. However, in some tumors, abnormal deposition of SDC1 in the tumor stroma or ectopic localization in the cytoplasm/nucleus of tumor cells is closely associated with poor prognosis. Additionally, tumor cells can release the extracellular domain of SDC1 (i.e., shedding) through metalloproteinase-mediated proteolysis, producing soluble SDC1 fragments that retain biological activity and can exert paracrine or competitive inhibitory effects in the circulatory system, interfering with normal cell signaling.

IV. Latest Research Progress on Syndecan-1 as a Liquid Biopsy Biomarker

In recent years, the potential of Syndecan-1 in the field of liquid biopsy has garnered widespread attention. In a study published in Clinical Cancer Research, a team from Lund University in Sweden developed a method combining size exclusion chromatography (SEC) for plasma extracellular vesicle (plEV) separation with proximity extension assay (PEA)-based ultrasensitive immunoassay to analyze nearly 200 proteins. In this study, researchers first identified SDC1 as a plEV protein component capable of distinguishing high-grade glioblastoma (GBM, WHO grade IV) from low-grade glioma (LGG, WHO grade II). The study found that plasma EV SDC1 levels in glioma patients were positively correlated with SDC1 protein expression in tumor tissues, and postoperative plEV SDC1 levels significantly decreased with the extent of surgical resection. SDC1 mRNA expression in tumors from an independent glioma patient cohort in The Cancer Genome Atlas (TCGA) also consistently distinguished GBM from LGG, with high SDC1 expression significantly associated with the mesenchymal subtype, IDH wild-type, and poorer overall patient survival. These findings provide important proof-of-concept for the application of EV proteomics in non-invasive brain tumor diagnosis, while suggesting that SDC1 may play a more active pro-tumor role in glioma biology, involving key pathways such as tumor stroma remodeling, hypoxia, angiogenesis, and EV biogenesis.

V. Conclusion

In summary, Syndecan-1/CD138, as a core member of the heparan sulfate proteoglycan family, with its unique glycosaminoglycan modification structure, broad ligand-binding capabilities, and differential expression patterns in plasma cells and various epithelial-derived tumors, has established its dual clinical value as a diagnostic marker for multiple myeloma and a candidate target for glioma liquid biopsy. The Alexa Fluor 647-Labeled Syndecan-1/CD138 His Tag Protein, Human provided by Uni offers a stable and reliable detection tool for SDC1-related receptor-ligand binding analysis, targeted drug screening, and CAR cell functional evaluation, thanks to its precise molecular design, native conformation ensured by human expression systems, stringent quality control, and excellent optical labeling performance.

This article is reviewed and published by the technical expert team of UA

Disclaimer: This article partially utilizes artificial intelligence assistance in its creation. If any content involves copyright or intellectual property issues, please let us know and we promise to verify and remove it as soon as possible.

Purchase recombinant protein, choose Nanjing UA-Bio

UA protein focuses on providing various protein reagents, raw materials, and services required for drug research and development, cell therapy, gene therapy, and basic scientific research, including drug target proteins, immune checkpoint proteins, cytokines, tool enzymes, customized protein expression, and full-length transmembrane protein development. Youai is committed to providing customers with high-quality products and professional services, and building a High-tech Biological Enterprise with International Competitiveness.

Buy antibodiesFind UA www.ua-bio.com | 15 years of protein development experience

Nanjing UA Biotechnology Co., Ltd. Email：order@ua-bio.com Phone：+86-25-56221161

more products

Product Information

The Last The Next